Silo Pharma Files 8-K on Shareholder Votes

TL;DR

Silo Pharma held a shareholder vote on 12/20/24, details to follow.

AI Summary

Silo Pharma, Inc. filed an 8-K on December 20, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented to shareholders.

Why It Matters

This filing indicates that Silo Pharma held a shareholder meeting where votes were cast on important company matters, the details of which are not yet fully disclosed in this initial report.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant
• December 20, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 677 N. Washington Boulevard (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar

Filing Documents

• ea0225567-8k_silopharma.htm (8-K) — 38KB
• 0001213900-24-111256.txt ( ) — 206KB
• silo-20241220.xsd (EX-101.SCH) — 3KB
• silo-20241220_lab.xml (EX-101.LAB) — 33KB
• silo-20241220_pre.xml (EX-101.PRE) — 22KB
• ea0225567-8k_silopharma_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 20, 2024, Silo Pharma Inc. (the "Company") held its annual meeting of shareholders, (the "Annual Meeting") for the purpose of holding a shareholder vote on the proposals set forth below. A total of 1,957,299 shares of the Company's common stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. At the Annual Meeting, the Company's shareholders (i) re-elected each of Eric Weisblum, Wayne Linsley, Kevin Munoz and Jeff Pavell as members of the Company's board of directors to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death; (ii) ratified the appointment of Salberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; (iii) approved the non-binding advisory vote on the resolution approving named executive officer compensation; (iv) approved the frequency for providing the non-binding advisory vote on named executive compensation at "3-years;" and (v) approved the authorization for the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting, as set forth in the Company's Definitive Proxy Statement, filed with the Securities and Exchange Commission on November 15, 2024, are as follows: Proposal 1 : At the Annual Meeting, the terms of all current members of the Company's board of directors expired. All of the five nominees for director were elected to serve until the next annual meeting of shareholders or until their respective successors

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: December 20, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR